Latest Breaking News On - Medicine at duke university school of - Page 1 : comparemela.com

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs

Temple universityUnited statesCorey davisVeronica eamesMark sulkowskiExchange commission onTemple university school of medicineAmerican association of liver disease onMedicine at duke university school ofExchange commissionJohns hopkins university school of medicineLifesci communicationsViral hepatitis centerDepartment of medicineInfectious diseases society of americaClinical trials group

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesTemple universityVeronica eamesMark sulkowskiCorey davisAmerican association of liver disease onAmerican society for clinical investigationLifesci communicationsDepartment of medicineExchange commissionAligos therapeutics incViral hepatitis centerInfectious diseases society of americaJohns hopkins university school of medicineMedicine at duke university school ofClinical trials group

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

November 16 Event to feature KOL perspective on Emerging HBV TherapiesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on.

United statesTemple universityCorey davisVeronica eamesMark sulkowskiExchange commission onDepartment of medicineJohns hopkins university school of medicineTemple university school of medicineAmerican association of liver disease onAmerican society for clinical investigationLifesci communicationsInfectious diseases society of americaViral hepatitis centerMedicine at duke university school ofClinical trials group

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Basel stadtSwitzerland generalVanceg fowler jrThomas hollandNils schrMarc engelhardtDevelopment authorityAdministration for strategic preparednessHead of corporate communications investor relationsBasilea pharmaceutica international ltdBiomedical advanced researchDrug administrationMedicine at duke university school ofUs department of healthHuman servicesSwiss exchange

Three years after the start of the pandemic, long COVID is a major concern for patients and doctors

Some who contracted COVID-19 continue to suffer from long COVID. We learn more about it, its impact and how it’s treated.

United statesAmanda staufferStephani sutherlandDuke healthMedicine at duke university school ofCoral giovacchiniDuke university schoolCovid symptomsCovid 19Dr coral giovacchiniDr stephani sutherlandLong covid